CR rates by induction therapy
| . | CR rate, % . | P . | |
|---|---|---|---|
| IDR group (n = 532) . | DNR group (n = 525) . | ||
| FAB type | |||
| M0 | 43 | 63 | .195 |
| M1 | 86 | 79 | .236 |
| M2 | 80 | 82 | .718 |
| M4 | 81 | 79 | .86 |
| M5 | 77 | 75 | .96 |
| M6 | 76 | 38 | .037 |
| M7 | 50 | 100 | .999 |
| Cytogenetic group | |||
| Favorable | 91 | 96 | .134 |
| Intermediate | 79 | 76 | .359 |
| Adverse | 51 | 43 | .534 |
| Unknown | 50 | 69 | .257 |
| Age, y | |||
| ≤ 50 | 83 | 77 | .108 |
| > 50 | 73 | 78 | .225 |
| Myeloperoxidase-positive blasts, % | |||
| < 50 | 68 | 66 | .709 |
| ≥ 50 | 87 | 88 | .699 |
| WBC at diagnosis, ×109/L | |||
| ≤ 20 | 79 | 76 | .767 |
| 20= ≤ 50 | 82 | 82 | .993 |
| > 50 | 74 | 77 | .824 |
| Performance status | |||
| 0, 1, 2 | 79 | 78 | .762 |
| 3 | 80 | 75 | .999 |
| . | CR rate, % . | P . | |
|---|---|---|---|
| IDR group (n = 532) . | DNR group (n = 525) . | ||
| FAB type | |||
| M0 | 43 | 63 | .195 |
| M1 | 86 | 79 | .236 |
| M2 | 80 | 82 | .718 |
| M4 | 81 | 79 | .86 |
| M5 | 77 | 75 | .96 |
| M6 | 76 | 38 | .037 |
| M7 | 50 | 100 | .999 |
| Cytogenetic group | |||
| Favorable | 91 | 96 | .134 |
| Intermediate | 79 | 76 | .359 |
| Adverse | 51 | 43 | .534 |
| Unknown | 50 | 69 | .257 |
| Age, y | |||
| ≤ 50 | 83 | 77 | .108 |
| > 50 | 73 | 78 | .225 |
| Myeloperoxidase-positive blasts, % | |||
| < 50 | 68 | 66 | .709 |
| ≥ 50 | 87 | 88 | .699 |
| WBC at diagnosis, ×109/L | |||
| ≤ 20 | 79 | 76 | .767 |
| 20= ≤ 50 | 82 | 82 | .993 |
| > 50 | 74 | 77 | .824 |
| Performance status | |||
| 0, 1, 2 | 79 | 78 | .762 |
| 3 | 80 | 75 | .999 |
CR indicates complete remission; IDR, idarubicin; DNR, daunorubicin; FAB, French-American-British classification; and WBC, white blood cell count.